zoledronic acid + denosumab

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Bone Metastases

Conditions

Bone Metastases

Trial Timeline

Apr 1, 2006 → Feb 24, 2012

NCT ID

NCT00321620

About zoledronic acid + denosumab

zoledronic acid + denosumab is a phase 3 stage product being developed by Amgen for Bone Metastases. The current trial status is completed. This product is registered under clinical trial identifier NCT00321620. Target conditions include Bone Metastases.

What happened to similar drugs?

10 of 20 similar drugs in Bone Metastases were approved

Approved (10) Terminated (1) Active (9)

🔄Denosumab + Zoledronic AcidDaiichi SankyoPhase 3

🔄Arzoxifene + PlaceboEli LillyPhase 3

🔄TanezumabEli LillyPhase 3

🔄Anastrozole + TamoxifenAstraZenecaPhase 3

🔄zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplementsNovartisPhase 3

🔄Zoledronic acidNovartisPhase 3

🔄Zoledronic acid + LetrozoleNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00321620	Phase 3	Completed	Apr 1, 2006	Feb 24, 2012	Bone Metastases

Competing Products

20 competing products in Bone Metastases

See all competitors

Product	Company	Stage	Hype Score
Denosumab + Zoledronic Acid	Daiichi Sankyo	Phase 3	40
Enzalutamide	Astellas Pharma	Phase 2	35
Enzalutamide	Astellas Pharma	Phase 2	35
Tacrolimus	Astellas Pharma	Phase 2	35
Tacrolimus	Astellas Pharma	Phase 2	35
Merestinib	Eli Lilly	Phase 1	21
FORTEO + Placebo	Eli Lilly	Phase 1	29
Arzoxifene + Placebo	Eli Lilly	Phase 3	40
Tanezumab	Eli Lilly	Phase 3	40
Anastrozole + Tamoxifen	AstraZeneca	Phase 3	40
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements	Novartis	Phase 3	40
Zoledronic acid	Novartis	Phase 3	40
Zoledronic acid + Letrozole	Novartis	Phase 3	40
Zoledronic acid	Novartis	Phase 3	40
Nilotinib	Novartis	Phase 1	29
Reclast (ZOL446, zoledronic acid)	Novartis	Approved	43
Zoledronic acid	Novartis	Phase 3	32
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid	Novartis	Phase 3	40
zoledronic acid	Novartis	Phase 1	29
Ruxolitinib continuous therapy	Novartis	Phase 2	39